AstraZeneca Secures Deutsche Bank Upgrade to 'Hold' as Analysts Project 24% Upside

Pharmaceutical giant AstraZeneca (AZN) has received a rating upgrade to 'Hold' from Deutsche Bank following its latest clinical trial outcomes. This adjustment comes amid a generally positive outlook from Wall Street, where the stock maintains a consensus 'Moderate Buy' rating. Over the past 12 months, seven analysts have evaluated the company, yielding six 'Buy' ratings and one 'Sell' rating.

Financial forecasts suggest significant growth potential for the drugmaker. The average 12-month price target for AstraZeneca is set at £151.14, indicating an estimated upside of 24.56% from current levels. Analyst projections span from a conservative low of £115 to an optimistic high of £178.

While the stock experienced one downgrade over the last 90 days, it has drawn active coverage from major institutions, including Berenberg Bank, Citigroup, Jefferies Financial Group, and Royal Bank of Canada. Furthermore, AstraZeneca continues to outpace the broader healthcare sector; its 'Moderate Buy' consensus stands in contrast to the industry's average 'Hold' rating.